Compare Bank China Construction Bank Indonesia Tbk. (MCOR) vs Brigit Biofarmaka Teknologi Tbk. (OBAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank China Construction Bank Indonesia Tbk. vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Bank China Construction Bank Indonesia Tbk. trades at Rp68 (market cap 2.55T, 485.4K 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp248 (market cap 167.37B, 96.7K 24h volume). The key difference: Bank China Construction Bank Indonesia Tbk. is far larger — about 15.2× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Bank China Construction Bank Indonesia Tbk. is more actively traded (485.4K versus 96.7K). Which is the better fit depends on your goals.
| MCOR | OBAT | |
|---|---|---|
Market Cap | 2.55T | 167.37B |
Volume | 485.4K | 96.7K |
Lot | 4.85K | 967 |
Turnover | 32.56M | 23.82M |
Average Price | 67.07 | 246.34 |
Value | 32.56M | 23.82M |
Indicative Equilibrium Price | 68 | 248 |
Indicative Equilibrium Volume | 2 | 41 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank China Construction Bank Indonesia Tbk.
PT Bank Multicor (Bank) was established under its original name of PT Multinational Finance Corporation base on notarial deed No.4 of Mr Bagijo, S.H, dated on Apr 2, 1974. The Company’s articles of association has been amended several times, most recently by notarial deed No. 143 of Eliwati Tjitra, S.H., dated Mar 21, 2007, concerning among others, the change in the Company’s name, Anggaran Dasar and public offering. The Bank's name was changed to PT Bank Windu Kentjana International Tbk.
Read more on MCOR →About Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →
